Efficacy of probiotic co-supplementation with omega-3 PUFAs on pancreatic beta-cell function in type 2 diabetes
Abstract
The current understanding of the beneficial effects of probiotics in type 2 diabetes (T2D) relies on both animal and clinical data, which focus mainly on their impact on insulin resistance. The use of high-dose omega-3 polyunsaturated fatty acid (PUFA) therapy has been well tolerated in pilot trials and could have a positive effect on the maintenance of β-cell function before and after T1D onset. This study evaluated the effectiveness of live multistrain probiotic co-supplementation with omega-3 PUFAs vs. placebo on β-cell function in T2D patients. We conducted a secondary analysis of a previously published RCT (NCT04201938, NCT03528707) with a total of 45 patients with T2D. The main inclusion criteria were the presence of β-cell dysfunction (%B < 50%) and insulin therapy alone or in combination with oral antidiabetic drugs. In the placebo group, all parameters changed insignificantly after treatment. Compared with the baseline value, supplementation with live multiprobiotic and omega-3 PUFAs was associated with marginally significant improvement in β-cell function (%B increased from 42.2 ± 15.4 to 62.21 ± 33.98; р=0.049). However, in the adjusted ANCOVA, a lack of significant differences compared with the placebo was detected. In the secondary outcome analysis, significant reductions in fasting plasma glucose, TNF-α levels, and anthropometric parameters, as well as improvements in insulin sensitivity, were noted.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 45 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.